West Pharmaceutical Services, Inc. (WST) To Go Ex-Dividend on April 29th

West Pharmaceutical Services, Inc. (NYSE:WST) announced a quarterly dividend on Monday, February 16th. Shareholders of record on Wednesday, April 29th will be paid a dividend of 0.22 per share by the medical instruments supplier on Wednesday, May 6th. This represents a c) annualized dividend and a yield of 0.4%. The ex-dividend date of this dividend is Wednesday, April 29th.

West Pharmaceutical Services has increased its dividend payment by an average of 0.1%per year over the last three years. West Pharmaceutical Services has a payout ratio of 12.4% meaning its dividend is sufficiently covered by earnings. Analysts expect West Pharmaceutical Services to earn $7.86 per share next year, which means the company should continue to be able to cover its $0.88 annual dividend with an expected future payout ratio of 11.2%.

West Pharmaceutical Services Price Performance

NYSE WST traded up $2.01 during trading on Wednesday, reaching $245.20. 269,382 shares of the company traded hands, compared to its average volume of 1,100,813. West Pharmaceutical Services has a 1-year low of $187.43 and a 1-year high of $322.34. The company has a market cap of $17.64 billion, a price-to-earnings ratio of 36.11, a P/E/G ratio of 3.27 and a beta of 1.18. The stock’s 50 day moving average price is $260.12 and its two-hundred day moving average price is $261.81. The company has a debt-to-equity ratio of 0.06, a quick ratio of 2.34 and a current ratio of 3.02.

West Pharmaceutical Services (NYSE:WST) last posted its earnings results on Thursday, February 12th. The medical instruments supplier reported $2.04 earnings per share for the quarter, topping the consensus estimate of $1.83 by $0.21. The business had revenue of $805.00 million for the quarter, compared to analyst estimates of $795.70 million. West Pharmaceutical Services had a net margin of 16.06% and a return on equity of 17.90%. The firm’s quarterly revenue was up 7.5% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $1.82 EPS. West Pharmaceutical Services has set its FY 2026 guidance at 7.850-8.200 EPS. As a group, analysts anticipate that West Pharmaceutical Services will post 6.62 EPS for the current year.

Institutional Investors Weigh In On West Pharmaceutical Services

Several hedge funds have recently added to or reduced their stakes in the business. Flagship Harbor Advisors LLC boosted its holdings in shares of West Pharmaceutical Services by 3.7% in the third quarter. Flagship Harbor Advisors LLC now owns 1,091 shares of the medical instruments supplier’s stock worth $286,000 after buying an additional 39 shares during the last quarter. NewEdge Wealth LLC raised its position in West Pharmaceutical Services by 3.5% in the third quarter. NewEdge Wealth LLC now owns 1,174 shares of the medical instruments supplier’s stock worth $333,000 after acquiring an additional 40 shares during the period. Darwin Wealth Management LLC boosted its stake in shares of West Pharmaceutical Services by 10.8% during the 4th quarter. Darwin Wealth Management LLC now owns 410 shares of the medical instruments supplier’s stock worth $113,000 after acquiring an additional 40 shares during the last quarter. RFG Advisory LLC boosted its stake in shares of West Pharmaceutical Services by 2.2% during the 3rd quarter. RFG Advisory LLC now owns 2,233 shares of the medical instruments supplier’s stock worth $586,000 after acquiring an additional 47 shares during the last quarter. Finally, Aptus Capital Advisors LLC grew its position in shares of West Pharmaceutical Services by 5.5% during the 4th quarter. Aptus Capital Advisors LLC now owns 905 shares of the medical instruments supplier’s stock valued at $249,000 after acquiring an additional 47 shares during the period. Institutional investors and hedge funds own 93.90% of the company’s stock.

About West Pharmaceutical Services

West Pharmaceutical Services, Inc is a global developer and manufacturer of components, systems and services that enable the containment and delivery of injectable drugs. The company focuses on high-quality packaging and delivery solutions for the pharmaceutical and biotech industries, producing primary drug packaging components and specialized drug delivery devices used for vaccines, biologics and other injectable therapies. West is known for its elastomeric closures, seals and polymer components that maintain sterility and compatibility with sensitive drug formulations.

In addition to component manufacturing, West provides engineered delivery systems and support services across the product lifecycle.